NORWICH – Douglas L. Drysdale was appointed Monday to the newly created position of chief executive officer of Norwich Pharmaceuticals, Inc. and its parent company. Drysdale will also be elected to the Board of Directors of Norwich’s parent company. Drysdale joins Norwich from Actavis Group hf. where he served as corporate vice president, mergers & acquisitions and as a member of the Group’s Executive Board.

Christopher R. Calhoun will continue serving as president of Norwich Pharmaceuticals, which will remain the company’s U. S. center of excellence for the production of high quality pharmaceuticals for its industry customers as well as, potentially, for its new commercial division.

“We are very excited to have someone of Doug’s caliber as our CEO,” said Calhoun. “His in-depth pharmaceutical experience will help Norwich diversify and grow, while remaining focused on the high standard of quality and uncommon value that our current and future customers expect.”